FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback